Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2021 07:30 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Present at the Needham Healthcare Conference

BEDMINSTER, N.J., April 08, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present...
March 29, 2021 06:30 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

– Matinas to internally focus on its Lipid Nanocrystal (LNC) platform to improve the intracellular delivery of critical therapeutics – – Enrollment continues in second patient cohort of EnACT study...
March 15, 2021 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results on March 29, 2021

BEDMINSTER, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics...
March 01, 2021 07:30 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Present at the Barclays Global Healthcare Conference

BEDMINSTER, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present...
February 01, 2021 06:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Against Vascepa®

– LYPDISO™ demonstrated a statistically significant 46% relative percent increase in EPA change from baseline over Vascepa® – – LYPDISO™ demonstrated a 39% relative difference in response...
January 06, 2021 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Present at the ICR Conference 2021

BEDMINSTER, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a...
January 04, 2021 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces FDA Conditional Acceptance of LYPDISO™ as the Brand Name for MAT9001

BEDMINSTER, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics...
December 07, 2020 06:35 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platform Delivery Technology

BEDMINSTER, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics...
December 07, 2020 06:30 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Files Preliminary Proxy for Special Meeting of Stockholders

- Special Meeting of Stockholders Scheduled for January 26, 2021 Seeking Authorization to Potentially Effectuate a Discretionary Reverse Stock Split Prior to January 26, 2022 - - Company’s Proposal...
December 01, 2020 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Appoints Hui Liu, Ph.D., M.B.A. as Chief Technology Officer

BEDMINSTER, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics...